SiBone (NASDAQ:SIBN) Insider Anshul Maheshwari Sells 3,247 Shares of Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 3,247 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $25.00, for a total transaction of $81,175.00. Following the transaction, the insider owned 211,250 shares in the company, valued at approximately $5,281,250. This trade represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The shares were sold at an average price of $22.50, for a total transaction of $84,105.00.
• On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total transaction of $33,754.50.
• On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The shares were sold at an average price of $18.18, for a total value of $60,321.24.
• On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The shares were sold at an average price of $20.11, for a total value of $233,999.96.
• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total value of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total value of $87,002.25.

SiBone Price Performance

NASDAQ SIBN traded down $0.03 during trading hours on Friday, reaching $24.24. The company’s stock had a trading volume of 683,472 shares, compared to its average volume of 638,581. SiBone has a 1 year low of $11.48 and a 1 year high of $25.92. The company has a quick ratio of 7.55, a current ratio of 7.58 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -78.19 and a beta of 0.64. The firm’s 50-day moving average price is $19.71 and its 200-day moving average price is $16.56.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The business had revenue of $55.70 million during the quarter, compared to analyst estimates of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. On average, equities research analysts predict that SiBone will post -0.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SIBN. D.A. Davidson & CO. increased its position in SiBone by 2.8% in the third quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock worth $711,000 after purchasing an additional 1,038 shares during the last quarter. First Light Asset Management LLC raised its stake in SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after purchasing an additional 2,774,795 shares in the last quarter. Squarepoint Ops LLC raised its stake in SiBone by 40.3% during the second quarter. Squarepoint Ops LLC now owns 118,128 shares of the company’s stock valued at $1,928,000 after purchasing an additional 33,947 shares in the last quarter. VELA Investment Management LLC lifted its position in SiBone by 7.4% during the second quarter. VELA Investment Management LLC now owns 201,094 shares of the company’s stock valued at $3,282,000 after purchasing an additional 13,934 shares during the last quarter. Finally, Corient Private Wealth LP lifted its position in SiBone by 119.6% during the second quarter. Corient Private Wealth LP now owns 43,946 shares of the company’s stock valued at $717,000 after purchasing an additional 23,938 shares during the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on SIBN shares. Needham & Company LLC cut their target price on shares of SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Tuesday. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. TD Cowen increased their price objective on shares of SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a report on Tuesday. Citigroup restated a “market outperform” rating on shares of SiBone in a research report on Tuesday. Finally, UBS Group lifted their target price on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.00.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.